台耀化學股份有限公司

Formosa Laboratories has been a dedicated supplier of Active Pharmaceutical Ingredients (APIs) for many years, particularly in the areas of polymers (such as cholesterol and phosphate absorbents) and the Vitamin D derivative producta. This long-standing focus has earned Formosa Laboratories a key position in the global API market.
With sustained investment in the R&D of Antibody-Drug Conjugates (ADCs) and CDMO services, Formosa Laboratories has successfully transformed into a globally competitive CDMO, provides one-stop services to clients globally. Recently, Formosa Laboratories has been actively pursuing vertical integration, including the establishment of injectable filling lines. Leveraging its extensive experience, the company aims to provide comprehensive, one-stop services — from raw material sourcing and process development to scale-up and final drug product manufacturing.
Formosa Laboratories also has established a platform for ADC development. Formosa Laboratories has supported numerous clients through the drug development, from laboratory research to IND-enabling across multiple countries. In response to rising market demand, Formosa Laboratories has completed the expansion of its ADC production facilities, enabling commercial-scale manufacturing and full CDMO services for large-volume production.
In 2023, Formosa Laboratories received drug certificate from Taiwan FDA for the anti-cancer drug “Eribulin Injectable.” Submission for other territories are ongoing to expand into global markets. Concurrently, Formosa Laboratories is in active discussions with international pharmaceutical partners for licensing opportunities of its injectable drug portfolio, aiming to enhance its global footprint.
Formosa Laboratories completed acquisition SynChem, now SynChem-Formosa in Chicago, USA, on June 1, 2024. This acquisition strengthens Formosa Laboratories R&D and CDMO services in North America and reinforces its global business footprint.
At BioAsia, Formosa Laboratories will present its end-to-end CDMO capabilities across APIs, ADCs, and injectable. The company is actively seeking partnerships with international clients and pursuing licensing opportunities for its self-developed products — all with the goal of accelerating global expansion.